Our result that Glut4 expression is not influenced by STZ-icv treatment is in accordance with unaltered GLUT4 protein levels in human AD brains (Liu et al. 2008; and correlates to abnormal hyperphosphorylation of tau) and in NSE/hPS2m Tg mice, a transgenic mouse model of AD (Lee et al. 2013), but is in contrast to the findings of Chen and coworkers, who demonstrated reduced GLUT4 protein concentrations in STZ-icv treated male Sprague–Dawley rats compared to controls (Chen et al. 2021). Here, MAPT is linked to Alzheimer disease.